paclitaxel has been researched along with Carcinoma, Squamous Cell of Head and Neck in 86 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 50 (58.14) | 24.3611 |
| 2020's | 36 (41.86) | 2.80 |
| Authors | Studies |
|---|---|
| Agostini, M; Almeida, LY; Bastos, DC; Coletta, RD; Cuadra Zelaya, FJM; Daher, URN; Graner, E; Kowalski, LP; Mariano, FS; Moreira, FDS; Ortiz, CA; Santos, GASD | 1 |
| Kirita, T; Kurita, H; Matsumura, T; Naruse, T; Okura, M; Ota, Y; Otsuru, M; Sasaki, M; Shintani, Y; Umeda, M; Yamada, SI; Yamakawa, N; Yanamoto, S | 1 |
| Abdeddaim, C; Clatot, F; Even, C; Guiard, E; Johnson, A; Perréard, M; Rambeau, A; Vauléon, E | 1 |
| Koo, P; Malin, M; Okereke, J | 1 |
| Chera, BS; Grilley-Olson, JE; Lenze, NR; Murr, AT; Patel, SA; Shen, C; Sheth, SH; Thorp, BD; Weiss, JM; Zanation, AM | 1 |
| Chera, B; Deal, AM; Gilbert, J; Hackman, T; Hayes, DN; Liao, JJ; Miller, K; Murphy, B; Olson, JG; Sheth, S; Weiss, J; Weissler, M; Woods, J | 1 |
| Di Fabio, F; Filippini, DM; Mosca, M; Rihawi, K; Rojas, FL; Tober, N | 1 |
| Fang, J; Feng, L; Huang, T; Wang, L; Wang, R; Yang, Y | 1 |
| Bhatia, AK; Burtness, B; Deshpande, H; Forman, R | 1 |
| Alamgeer, M; Coleman, A; Giddings, C; McDowell, L; Safdar, A; Sigston, E; Subramaniam, A; Wang, Y | 1 |
| Hara, H; Hashimoto, K; Jiromaru, R; Komune, N; Kuratomi, Y; Manako, T; Masuda, M; Matsuo, M; Nakagawa, T; Nishimura, E; Takeuchi, T; Toh, S; Wakasaki, T; Yamauchi, M; Yasumatsu, R | 1 |
| Chang, X; Chen, L; Chen, X; Gao, J; Gooding, JJ; Mu, W; Sun, S; Tian, R; Wu, Q; Wu, Y; Yang, G | 1 |
| Givi, B; Kim, S; Samant, S; Talwar, A; Tozan, Y; Yu, S | 1 |
| Chen, Y; Dong, M; Dou, S; Huang, Y; Ju, W; Li, J; Liu, Y; Shi, W; Sun, J; Sun, Q; Tang, Y; Zhang, D; Zhao, T; Zhong, L; Zhou, X; Zhou, Z; Zhu, D; Zhu, G; Zhu, Q | 1 |
| Chen, L; Gelblum, D; Han, J; Hesse, J; Kang, JJ; Lee, NY; McBride, SM; Michel, L; Raab, G; Riaz, N; Shamseddine, A; Sherman, EJ; Tsai, CJ; Wong, RJ; Yu, Y; Zakeri, K | 1 |
| Kohn, N; Locke, M; Seetharamu, N | 1 |
| Cao, F; Fang, Q; Liu, X; Wu, D; Xu, P | 1 |
| Enokida, T; Fujisawa, T; Hoshi, Y; Ishii, G; Okano, S; Onaga, R; Sakashita, S; Sato, M; Tahara, M; Takeshita, N; Tanaka, H; Tanaka, N; Wada, A | 1 |
| Carvalho, AL; Iyer, NG; Leong, HS; Lim, SK; Melendez, ME; Ramos, CRN; Rodrigues-Junior, DM; Tan, DSW; Tan, SS; Vettore, AL; Viana, LS | 1 |
| Gong, L; Gross, N; Lei, D; Li, G; Li, X; Luo, X; Zeng, Q; Zhang, M; Zhang, S; Zhang, Z; Zhou, Z | 1 |
| Adkins, DR; Daly, M; Gay, HA; Jackson, R; Johnson, KCC; Ley, J; Lu, J; Oppelt, P; Paniello, RC; Pipkorn, P; Rich, J; Thorstad, W; Zevallos, J | 1 |
| Hamauchi, S; Kawakami, T; Mori, K; Ogawa, H; Onitsuka, T; Onoe, T; Onozawa, Y; Shirasu, H; Yokota, T | 1 |
| Baste, N; Even, C; Herrera Gómez, RG; Iacob, M; Mayache, L; Saleh, K | 1 |
| Doi, K; Fumita, S; Haratani, K; Hayashi, H; Ishikawa, K; Iwasa, T; Kanemura, H; Kitano, M; Kurosaki, T; Mitani, S; Nakagawa, K; Nishimura, Y; Otsuki, N; Suzuki, S; Tanaka, K; Yoshida, T | 1 |
| Choi, HS; Hwang, KG; Kim, YK; Yun, PY | 1 |
| Pradhan, GS; Rathi, AK; Singh, K; Sunku, R | 1 |
| Cabezas-Camarero, S; Cabrera-Martin, MN; Perez-Segura, P; Saiz-Pardo Sanz, M | 1 |
| Bellanger, C; Classe, M; Even, C; Garcia, G; Saleh, K | 1 |
| Nagasaka, M; Nguyen, A | 1 |
| Duz, MB; Karatas, OF | 1 |
| de Souza, JA; Foster, NR; Jelinek, MJ; Munster, PN; Schwartz, GK; Seiwert, TY; Vokes, EE; Zoroufy, AJ | 1 |
| Adkins, D; Daly, M; Gay, H; Gitau, M; Jackson, RS; Ley, J; Liu, J; Neupane, P; Oppelt, P; Palka, K; Paniello, R; Pipkorn, P; Powell, S; Rich, J; Spanos, WC; Thorstad, W; Zevallos, J | 1 |
| Beppu, S; Hanai, N; Kadowaki, S; Motai, R; Nishikawa, D; Sasaki, E; Sawabe, M; Suzuki, H; Terada, H | 1 |
| Adansa, JC; Caballero, J; Cirauqui Cirauqui, B; Iglesias Docampo, L; Lambea Sorrosal, J; Lozano Borbalas, A; Marruecos Querol, J; Martínez-Trufero, J; Mesía Nin, R; Ortega Izquierdo, E; Pajares Bernad, I; Plana Serrahima, M; Planas Toledano, I; Ponce Ortega, JM; Rubió-Casadevall, J; Taberna Sanz, M | 1 |
| Bharadwaj, R; Medhi, S | 1 |
| Alfonsi, M; Chevalier, T; Daste, A; Dupuis, C; Fakhry, N; Fayette, J; Huguet, F; Lambert, T; Le Tourneau, C; Loundou, A; Peyrade, F; Peyraud, F; Reure, J; Saada-Bouzid, E; Salas, S; Toullec, C | 1 |
| Aguilar, MR; Martín-Hita, A; Palao-Suay, R; Riestra-Ayora, J; Sánchez-Rodríguez, C; Sanz-Fernández, R; Yanes-Díaz, J | 1 |
| Kii, T; Sakuma, K; Tanaka, A | 1 |
| Adomako, A; McDaid, HM; Rodriguez-Gabin, A; Samaraweera, L | 1 |
| Adkins, D; Daly, M; Gay, HA; Jackson, R; Ley, J; Nussenbaum, B; Oppelt, P; Paniello, RC; Pipkorn, P; Rich, J; Thorstad, W; Trinkaus, K; Wildes, TM | 1 |
| Fukushima, H; Kawabata, K; Marshall, S; Mitani, H; Nakano, K; Sasaki, T; Sato, Y; Shimbashi, W; Taira, S; Takahashi, S; Tomomatsu, J; Yonekawa, H | 1 |
| Baxi, SS; Dunn, LA; Fury, MG; Haque, S; Ho, AL; Katabi, N; Korte, S; Pfister, C; Pfister, DG; Sherman, EJ; Xiao, H | 1 |
| Carvalho, AL; Cordeiro, FB; da Silva, IDCG; de Souza Viana, L; Laus, AC; Lo Turco, EG | 1 |
| Bartscht, T; Hakim, SG; Idel, C; Rades, D | 1 |
| Bou-Gharios, G; Hira-Miyazawa, M; Hirai, M; Kawashiri, S; Kitahara, H; Kobayashi, Y; Nakamura, H | 1 |
| Hara, H; Hasegawa, Y; Homma, A; Kiyota, N; Minato, K; Muro, K; Onoe, T; Saijo, K; Suzuki, M; Taguchi, J; Tahara, M; Takahashi, S; Ueda, S; Yamanaka, T; Yane, K; Yokota, T | 1 |
| Borel, C; Burgy, M; Leblanc, J | 1 |
| Abdallah, N; Nagasaka, M; Sukari, A | 1 |
| Ceballos, L; Freije, A; Gandarillas, A; García-Reija, F; Morales-Angulo, C; Obeso, S; Sanz, JR; Sanz-Gómez, N | 1 |
| Eich, HT; Elsayad, K; Haverkamp, U; Maring, S; Rehkämper, J; Rudack, C; Stenner, M; Wardelmann, E | 1 |
| Blumenschein, GR; Garden, AS; Ginsberg, LE; Glisson, BS; Gold, KA; Haddad, RI; Hutcheson, K; Johnson, FM; Kies, MS; Lee, JJ; Lewis, J; Lin, HY; Massarelli, E; Myers, J; Papadimitrakopoulou, V; Pharaon, RR; Pickering, C; Rabinowits, G; Tishler, RB; William, WN; Williams, MD | 1 |
| Killock, D | 1 |
| Arai, A; Hirano, S; Kinoshita, S; Konishi, E; Mitsuda, J; Mori, D; Ozawa, S; Saburi, S; Takenaka, M; Tsujikawa, T; Yoshimura, K | 1 |
| Komune, N; Matsuo, M; Nakagawa, T; Taura, M; Uchi, R; Wakasaki, T; Yasumatsu, R | 1 |
| Griessmann, M; Landgraf, V; Polednik, C; Roller, J; Schmidt, M | 1 |
| Alcaraz, D; Caballero, M; Feliz, L; Grau, JJ; Muñoz-García, C; Pereira, V; Sosa, AE | 1 |
| Clark, JI; Kucuk, O; Malhotra, B; Moon, J; Urba, SG; Wolf, GT; Worden, FP | 1 |
| Dyckhoff, G; Gal, Z; Grabe, N; Herold-Mende, C; Lahrmann, B; Rigalli, JP; Theile, D; Warta, R; Weiss, J | 1 |
| Dutta, PR; Fury, MG; Gelblum, DY; Haque, S; Katabi, N; Kurz, S; Lee, JL; Lee, NY; Mueller, B; Ng, KK; Pfister, DG; Rao, SS; Shen, R; Sherman, EJ; Smith-Marrone, S; Wolden, S | 1 |
| Armes, SP; Avila-Olias, M; Battaglia, G; Canton, I; Cecchin, D; Colley, HE; Hearnden, V; Hu, K; MacNeil, S; Madsen, J; McKeating, JA; Murdoch, C; Thornhill, MH; Warren, N | 1 |
| Deng, W; Guan, Z; Huang, M; Huang, W; Jiang, W; Kang, T; Li, L; Li, S; Liu, Q; Liu, R; Pan, C; Tan, W; Thomas, GR; Wu, J; Ye, W; Ying, X; Zeng, M; Zhang, L | 1 |
| Burtness, BA; Forastiere, AA; Kosmidis, EK; Lee, JW; Pectasides, E; Psyrri, A; Rimm, DL; Vassilakopoulou, M; Wanebo, HJ | 1 |
| Bayley, A; Chan, K; Chen, EX; Chin, S; Diaz-Padilla, I; Hope, A; Hossain, M; Kim, J; Loong, HH; Palma, D; Razak, AR; Read, N; Siu, LL; Waldron, J; Wang, L; Winquist, E | 1 |
| Chen, H; Cheng, L; Huang, JM; Tao, L; Tian, J; Xin, Y; Zhou, L | 1 |
| Adkins, DR; Diaz, J; Gay, H; Lewis, J; Ley, J; Michel, L; Nussenbaum, B; Paniello, RC; Rich, J; Schell, A; Thorstad, W; Trinkaus, K; Wildes, TM; Wu, N | 1 |
| Arnold, SM; Brill, Y; Dressler, EV; Gleason, JF; Kudrimoti, M; Silver, NL; Valentino, J | 1 |
| Bhasker, S; Biswas, A; Gandhi, AK; Mohanti, BK; Raza, MW; Roy, S; Saxena, T; Sharma, A; Thakar, A | 1 |
| Maushagen, R; Pries, R; Wollenberg, B | 1 |
| Hahlbrock, A; Maushagen, R; Pfannerstill, AC; Pries, R; Rades, D; Rahmanzadeh, R; Reers, S; Stauber, R; Wollenberg, B | 1 |
| Borel, C; Ciftci, S; Debry, C; Dupret-Bories, A; Schmaltz, H; Schultz, P; Takeda-Raguin, C | 1 |
| Grauer, D; Henry, D; Kathol, E; Narveson, L; Neupane, P; Rockey, M | 1 |
| Han, HY; Jeong, SH; Kim, H; Kim, HJ; Kim, JH; Lee, HE; Ryu, MH | 1 |
| Adkins, D; Daly, M; Gay, HA; Jackson, R; Ley, J; Michel, L; Nussenbaum, B; Paniello, R; Rich, J; Thorstad, W; Trinkaus, K; Uppaluri, R; Wildes, TM | 1 |
| Hakim, SG; Rades, D; Schild, SE; Seidl, D; Wollenberg, B | 1 |
| Chen, L; Chen, Y; Cheng, B; Tang, Q; Xie, M; Zhao, J; Zhou, X | 1 |
| Adansa Klain, JC; Berrocal, A; Caballero Daroqui, J; Cruz-Hernández, JJ; Del Barco Morillo, E; González-Rivas, C; Martínez-Galán, J; Martínez-Trufero, J; Mesía, R; Pastor Borgoñon, M; Vázquez Fernández, S; Vera, R | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Adkins, D; Daly, K; Ley, J; Oppelt, P; Wildes, TM | 1 |
| Bertholet, V; Dyckhoff, G; Efferth, T; Haefeli, WE; Herold-Mende, C; Ketabi-Kiyanvash, N; Theile, D; Weiss, J | 1 |
| Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Takahashi, H; Tsukuda, M | 1 |
| Cullen, KJ; Goloubeva, O; Kwok, Y; Ord, R; Parekh, A; Strome, S; Suntharalingam, M; Taylor, R; Wolf, J; Zimrin, A | 1 |
| Knecht, R; Laban, S; Münscher, A; Schafhausen, P; Tribius, S; Wang, CJ | 1 |
| Cmelak, AJ; Diaz, R; Kirby, W; Murphy, BA; Murphy, P; Netterville, JL; Shakhtour, B; Shyr, Y; Sinard, RJ; Thorpe, SW; Vlacich, G; Yarbrough, WG | 1 |
| Adkins, D; Dehdashti, F; Gay, H; Lewis, J; Ley, J; Mehan, P; Nussenbaum, B; Siegel, BA; Thorstad, W; Trinkaus, K; Wildes, T | 1 |
| Akervall, J; Galoforo, S; Geddes, TJ; Grénman, R; Marples, B; Thibodeau, BJ; Wilson, GD | 1 |
| Abhold, E; Altuna, X; Blair, KJ; Fan, JB; Kiang, A; Kuo, SZ; Ongkeko, WM; Rahimy, E; Wang-Rodriguez, J | 1 |
2 review(s) available for paclitaxel and Carcinoma, Squamous Cell of Head and Neck
| Article | Year |
|---|---|
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Survival Rate | 2018 |
Molecular targeting agents in the context of primary chemoradiation strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease Progression; ErbB Receptors; Fluorouracil; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Oropharyngeal Neoplasms; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
20 trial(s) available for paclitaxel and Carcinoma, Squamous Cell of Head and Neck
| Article | Year |
|---|---|
Circulating extracellular vesicle-associated TGFβ3 modulates response to cytotoxic therapy in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Drug Resistance, Neoplasm; Extracellular Vesicles; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiation Tolerance; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor beta3 | 2019 |
Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Rate | 2021 |
A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Female; Humans; Male; Middle Aged; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Young Adult | 2021 |
nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2021 |
Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Early Termination of Clinical Trials; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Organ Sparing Treatments; Paclitaxel; Panitumumab; Progression-Free Survival; Spain; Squamous Cell Carcinoma of Head and Neck | 2021 |
nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials, Phase II as Topic; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2017 |
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Sirolimus; Squamous Cell Carcinoma of Head and Neck | 2017 |
Is Lipidomic the Answer to the Search of a Biomarker for Organ Preservation Protocol in Head and Neck Squamous Cell Carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Head and Neck Neoplasms; Humans; Lipids; Paclitaxel; Saliva; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2018 |
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Squamous Cell Carcinoma of Head and Neck | 2018 |
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck | 2019 |
Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).
Topics: Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Intensity-Modulated; Squamous Cell Carcinoma of Head and Neck | 2014 |
Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma.
Topics: Adenoviridae; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Endostatins; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Recombinant Proteins; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-akt; ras Proteins; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Tissue Array Analysis | 2014 |
Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Oropharyngeal Neoplasms; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2014 |
Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2015 |
nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2016 |
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Panitumumab; Squamous Cell Carcinoma of Head and Neck | 2016 |
Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Drug Administration Schedule; ErbB Receptors; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Papillomaviridae; Prospective Studies; Remission Induction; Squamous Cell Carcinoma of Head and Neck | 2012 |
A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Gastrostomy; Head and Neck Neoplasms; Humans; Male; Middle Aged; Osteonectin; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
64 other study(ies) available for paclitaxel and Carcinoma, Squamous Cell of Head and Neck
| Article | Year |
|---|---|
FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin B1; Fatty Acid Synthase, Type I; Fatty Acid Synthases; Fluorouracil; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Orlistat; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2023 |
Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease Progression; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Time Factors | 2021 |
Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Aged; Bridged-Ring Compounds; Disease Progression; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2021 |
A 31-Year-Old Pregnant Woman With Asthma, Presenting With Worsening Dyspnea, Wheeze, and Hoarseness.
Topics: Adult; Antineoplastic Agents; Asthma; Carboplatin; Cesarean Section; Cyclin-Dependent Kinase Inhibitor p16; Deglutition Disorders; Diagnosis, Differential; Female; Hoarseness; Humans; Laryngeal Neoplasms; Laryngoscopy; Paclitaxel; Papillomavirus Infections; Pregnancy; Pregnancy Complications, Neoplastic; Radiotherapy; Squamous Cell Carcinoma of Head and Neck; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Sinonasal Squamous Cell Carcinoma Survival Outcomes Following Induction Chemotherapy vs Standard of Care Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Humans; Induction Chemotherapy; Neoplasm Staging; Paclitaxel; Paranasal Sinus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Standard of Care | 2022 |
Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2022 |
Unexpected response to fourth-line paclitaxel in a patient with metastatic oropharyngeal squamous cell carcinoma, immunotherapy-refractory: a case report.
Topics: Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Quality of Life; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment | 2022 |
miR-211-3p enhances induction chemotherapy insensitivity by upregulating CSF2/CCL20/TNF signaling in hypopharyngeal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CCL20; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Ligands; MicroRNAs; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Tumor Necrosis Factors | 2022 |
Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Frail Elderly; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2022 |
Treatment outcomes of standard (high dose) cisplatin and non-standard chemotherapy for locally advanced head and neck cancer.
Topics: Adult; Carboplatin; Cisplatin; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2023 |
Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2022 |
A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis-Targeting Chimeras Enhanced Immunotherapy.
Topics: Head and Neck Neoplasms; Humans; Immunotherapy; Nanogels; Paclitaxel; Proteolysis; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment | 2023 |
Private Payer-Negotiated Rates for FDA-Approved Head and Neck Cancer Immunotherapy and Chemotherapy Agents.
Topics: Antineoplastic Agents; Biological Products; Carboplatin; Cross-Sectional Studies; Head and Neck Neoplasms; Humans; Immunotherapy; Nivolumab; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2023 |
Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Microenvironment | 2023 |
Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2023 |
Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2023 |
PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Laryngeal Neoplasms; Larynx; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Quality of Life; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |
Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |
High Notch1 expression affects chemosensitivity of head and neck squamous cell carcinoma to paclitaxel and cisplatin treatment.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Dipeptides; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Receptor, Notch1; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2019 |
nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Papillomavirus Infections; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2019 |
Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2020 |
Panitumumab as an effective maintenance treatment in metastatic squamous cell carcinoma of the head and neck.
Topics: Anaphylaxis; Antineoplastic Agents; Antineoplastic Agents, Immunological; Carboplatin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Maintenance Chemotherapy; Male; Middle Aged; Neoplasms, Second Primary; Paclitaxel; Palliative Care; Panitumumab; Progression-Free Survival; Randomized Controlled Trials as Topic; Research Design; Squamous Cell Carcinoma of Head and Neck; Tongue Neoplasms | 2021 |
Increased FOXM1 Expression by Cisplatin Inhibits Paclitaxel-Related Apoptosis in Cisplatin-Resistant Human Oral Squamous Cell Carcinoma (OSCC) Cell Lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2020 |
Predicting outcome of advanced head-and-neck cancer by measuring tumor blood perfusion in patients receiving neoadjuvant chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Perfusion Imaging; Prognosis; Prospective Studies; Squamous Cell Carcinoma of Head and Neck; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Young Adult | 2020 |
Major and durable response to second-line pembrolizumab-carboplatin-paclitaxel in an oral cavity cancer patient.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Frailty; Head and Neck Neoplasms; Humans; Malnutrition; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2021 |
Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait.
Topics: Adult; Antineoplastic Agents, Immunological; Colitis, Ulcerative; Hashimoto Disease; Humans; Immune Checkpoint Inhibitors; Male; Nivolumab; Paclitaxel; Programmed Cell Death 1 Receptor; Remission Induction; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Time Factors; Tongue Neoplasms; Treatment Failure | 2021 |
Forget me not - Incorporating standard chemotherapy in an exciting era of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Head and Neck Neoplasms; Humans; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2021 |
Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial Cells; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Multidrug Resistance-Associated Protein 2; Neoplasm Proteins; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2021 |
Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2021 |
Effectual nanotherapy against oral squamous cell carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Carriers; Folic Acid; Head and Neck Neoplasms; Mouth Neoplasms; Nanoparticles; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Tissue Distribution | 2021 |
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Confidence Intervals; Disease Progression; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Progression-Free Survival; Propensity Score; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2021 |
Paclitaxel-loaded polymeric nanoparticles based on α-tocopheryl succinate for the treatment of head and neck squamous cell carcinoma:
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Drug Carriers; Female; Head and Neck Neoplasms; Mice; Mice, Nude; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Polymers; Squamous Cell Carcinoma of Head and Neck; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
PTEN Is Activated by the Addition of Cetuximab to Paclitaxel in Oral Squamous Cell Carcinoma.
Topics: Apoptosis; Cell Line, Tumor; Cetuximab; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Squamous Cell Carcinoma of Head and Neck | 2021 |
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cellular Senescence; Dose-Response Relationship, Drug; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Paclitaxel; Panobinostat; Squamous Cell Carcinoma of Head and Neck | 2017 |
A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2017 |
Re-irradiation with 36 Gy (1.5 Gy Twice Daily) Plus Paclitaxel for Advanced Recurrent and Previously Irradiated SCCHN is Feasible.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Re-Irradiation; Squamous Cell Carcinoma of Head and Neck | 2018 |
Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Topics: B7-H1 Antigen; Carcinoma, Squamous Cell; Cell Line, Tumor; Coculture Techniques; Dendritic Cells; Female; Head and Neck Neoplasms; Humans; Male; Matrix Metalloproteinase 13; Matrix Metalloproteinase 7; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Paclitaxel; Recombinant Proteins; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment | 2018 |
Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Programmed Cell Death 1 Receptor; Squamous Cell Carcinoma of Head and Neck | 2018 |
Response of head and neck epithelial cells to a DNA damage-differentiation checkpoint involving polyploidization.
Topics: Biopsy, Needle; Cell Cycle Checkpoints; Cell Proliferation; Cells, Cultured; Cyclin E; DNA Damage; Doxorubicin; Epithelial Cells; Female; Humans; Keratinocytes; Male; Nocodazole; Oncogene Proteins; Paclitaxel; Real-Time Polymerase Chain Reaction; Sensitivity and Specificity; Squamous Cell Carcinoma of Head and Neck | 2018 |
Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Deglutition Disorders; Disease-Free Survival; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Squamous Cell Carcinoma of Head and Neck | 2018 |
Towards risk-stratified induction regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Paclitaxel; Papillomavirus Infections; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2019 |
Radiation-induced angiosarcoma of the parotid gland after postoperative radiotherapy for hypopharyngeal carcinoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Diagnosis, Differential; Female; Hemangiosarcoma; Humans; Hypopharyngeal Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Paclitaxel; Parotid Neoplasms; Radiotherapy, Adjuvant; Squamous Cell Carcinoma of Head and Neck | 2019 |
Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nivolumab; Oxonic Acid; Paclitaxel; Palliative Care; Progression-Free Survival; Retrospective Studies; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Tegafur; Treatment Failure | 2020 |
DL-Methadone as an Enhancer of Chemotherapeutic Drugs in Head and Neck Cancer Cell Lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cisplatin; Doxorubicin; Fluorouracil; Head and Neck Neoplasms; Humans; Methadone; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2019 |
Outcome of patients treated with palliative weekly paclitaxel plus cetuximab in recurrent head and neck cancer after failure of platinum-based therapy.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Failure; Treatment Outcome | 2014 |
Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Head and Neck Neoplasms; Heterografts; Humans; Ki-67 Antigen; Mice, Inbred NOD; Mice, SCID; Multidrug Resistance-Associated Proteins; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2014 |
Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Dimyristoylphosphatidylcholine; Doxorubicin; Drug Delivery Systems; Head and Neck Neoplasms; Humans; Hydrogen-Ion Concentration; Paclitaxel; Polymethacrylic Acids; Squamous Cell Carcinoma of Head and Neck | 2014 |
Cisplatin and paclitaxel target significant long noncoding RNAs in laryngeal squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Delivery Systems; Female; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Paclitaxel; RNA, Long Noncoding; Squamous Cell Carcinoma of Head and Neck | 2014 |
p16INK4a Status and Response to Induction Low-Dose Fractionated Radiation in Advanced Head and Neck Cancer.
Topics: Adult; Antineoplastic Agents; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Female; Gene Expression Profiling; Genes, p16; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Papillomavirus Infections; Remission Induction; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2015 |
Treatment of squamous cell carcinoma of external auditory canal: A tertiary cancer centre experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Child; Cisplatin; Disease-Free Survival; Ear Canal; Ear Neoplasms; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Neck Dissection; Neoadjuvant Therapy; Neoplasm Staging; Otologic Surgical Procedures; Paclitaxel; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Tertiary Care Centers; Treatment Outcome; Young Adult | 2016 |
[Chemotherapy with paclitaxel leads to microRNA release].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy; Head and Neck Neoplasms; Humans; MicroRNAs; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Effects of paclitaxel on permanent head and neck squamous cell carcinoma cell lines and identification of anti-apoptotic caspase 9b.
Topics: Alternative Splicing; Antineoplastic Agents, Phytogenic; Apoptotic Protease-Activating Factor 1; Carcinoma, Squamous Cell; Caspase 9; Cell Cycle; Cell Death; Cell Line, Tumor; DNA Methylation; Enzyme Activation; Head and Neck Neoplasms; Humans; Membrane Potential, Mitochondrial; Paclitaxel; Promoter Regions, Genetic; Squamous Cell Carcinoma of Head and Neck; Staurosporine | 2016 |
Induction chemotherapy before surgery for unresectable head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Mouth Neoplasms; Oropharyngeal Neoplasms; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2016 |
Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Disease-Free Survival; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Rate | 2016 |
Kochia scoparia induces apoptosis of oral cancer cells in vitro and in heterotopic tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bassia scoparia; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Fruit; Head and Neck Neoplasms; Humans; Male; Methanol; Mice, Inbred C3H; Mouth Neoplasms; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Poly(ADP-ribose) Polymerases; Signal Transduction; Solvents; Squamous Cell Carcinoma of Head and Neck; Tumor Burden | 2016 |
Radiochemotherapy with Paclitaxel for Recurrent Previously Irradiated Squamous Cell Carcinoma of the Head and Neck.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Head and Neck Neoplasms; Humans; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2016 |
Circadian Clock Gene Bmal1 Inhibits Tumorigenesis and Increases Paclitaxel Sensitivity in Tongue Squamous Cell Carcinoma.
Topics: Animals; Antineoplastic Agents; ARNTL Transcription Factors; Blotting, Western; Carcinogenesis; Carcinoma, Squamous Cell; Chromatin Immunoprecipitation; Circadian Clocks; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genes, Tumor Suppressor; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Polymerase Chain Reaction; Squamous Cell Carcinoma of Head and Neck; Tongue Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Polyethylene Glycols; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2017 |
Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytostatic Agents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Head and Neck Neoplasms; Humans; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2011 |
Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
Topics: Adenoviridae Infections; Adenovirus E1A Proteins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bacterial Proteins; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, myc; Head and Neck Neoplasms; Humans; Neoplasms, Squamous Cell; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Receptors, Virus; RNA, Messenger; S Phase; Squamous Cell Carcinoma of Head and Neck; Streptolysins; Telomerase | 2011 |
Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Randomized Controlled Trials as Topic; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2012 |
Isolation and genomic characterization of stem cells in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cell Separation; Cisplatin; Flow Cytometry; Gene Expression Regulation, Neoplastic; Genomics; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Neoplastic Stem Cells; Paclitaxel; Radiation Tolerance; Sensitivity and Specificity; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured | 2013 |
Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt.
Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Interactions; Enzyme Activation; Epithelial-Mesenchymal Transition; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; MicroRNAs; Mitogen-Activated Protein Kinase 7; Neoplastic Stem Cells; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrans; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck | 2012 |